Grail (NASDAQ:GRAL) Coverage Initiated at Morgan Stanley

Equities researchers at Morgan Stanley started coverage on shares of Grail (NASDAQ:GRAL) in a research note issued to investors on Wednesday, Marketbeat reports. The firm set an “equal weight” rating and a $16.00 price target on the stock. Morgan Stanley’s price objective would indicate a potential downside of 8.31% from the stock’s current price.

A number of other research firms have also recently weighed in on GRAL. Wolfe Research assumed coverage on Grail in a report on Friday, November 15th. They issued a “peer perform” rating for the company. Guggenheim began coverage on Grail in a research note on Thursday, October 17th. They set a “neutral” rating for the company.

Grail Price Performance

Shares of Grail stock opened at $17.45 on Wednesday. The stock has a 50-day moving average price of $14.29. Grail has a fifty-two week low of $12.33 and a fifty-two week high of $23.36.

Insider Transactions at Grail

In other Grail news, CEO Robert P. Ragusa sold 123,454 shares of the firm’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $14.02, for a total value of $1,730,825.08. Following the transaction, the chief executive officer now owns 612,661 shares in the company, valued at approximately $8,589,507.22. This trade represents a 16.77 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Aaron Freidin sold 30,452 shares of Grail stock in a transaction on Monday, November 18th. The stock was sold at an average price of $14.02, for a total transaction of $426,937.04. Following the sale, the chief financial officer now directly owns 268,277 shares in the company, valued at approximately $3,761,243.54. This trade represents a 10.19 % decrease in their position. The disclosure for this sale can be found here. Insiders purchased 58,829 shares of company stock valued at $757,298 over the last 90 days.

About Grail

GRAIL, Inc, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.